A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Trinomab

Status: Enrolling

Conditions: Tetanus

Treatments: Drug: Siltartoxatug Injection (Brand name: Sintetol®)

Study type: Observational

Funder types: Industry

Identifiers

NCT07107932

TNM002-402

Details and patient eligibility

About

The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Enrollment: 10,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury;
• 2. Provided signed informed consent by themselves or their legal representatives.

Exclusion criteria

• None

Trial design

10,000 participants in 1 patient group

Siltartoxatug Injection (Brand name: Sintetol®)

Treatment:

Drug: Siltartoxatug Injection (Brand name: Sintetol®)